Market Update (NASDAQ:ESRX): Express Scripts says AbbVie drug could displace Sovaldi on formulary

[Reuters] – Pharmacy benefit manager Express Scripts Holding Co said it may quickly change its preferred drug formulary to favor an expected new hepatitis C drug from AbbVie if it is clinically equivalent . . . → Read More: Market Update (NASDAQ:ESRX): Express Scripts says AbbVie drug could displace Sovaldi on formulary Similar Articles: Stock Update (NASDAQ:ESRX): Express Scripts Announces 3rd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point Market Update (NASDAQ:ESRX): Express Scripts Holding Company Announces Third Quarter 2014 Earnings Conference Call Express Scripts Holding Company (NASDAQ:ESRX) – GSK gets a lift as Express Scripts reinstates lung drug Advair